Jeffrey Jerome Ludwig - Feb 10, 2023 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
Chief Commercial Officer
Signature
/s/ Gordon Esplin as attorney-in-fact for Jeffrey Jerome Ludwig
Stock symbol
PBYI
Transactions as of
Feb 10, 2023
Transactions value $
$0
Form type
4
Date filed
2/14/2023, 03:50 PM
Previous filing
Jan 5, 2023
Next filing
Jul 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Award $0 +67K +115.36% $0.00 125K Feb 10, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBYI Stock Option (Right to Buy) Award $0 +93K $0.00 93K Feb 10, 2023 Common Stock 93K $4.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Grantee's continued service with the Company through the applicable vesting date.
F2 Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Optionee's continued service with the Company through the applicable vesting date.